Myriad Genetics Inc (MYGN) Stock Price, Quote & News

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 801 584 3600

Fax: 801 584 3640

Website: www.myriad.com

Address:

322 North 2200 West, Salt Lake City, United States

OkieDokieTrader Sep. 11 at 4:03 PM

$MYGN literally at the edge of a massive break out. The wick from todays opening is all I needed to enter.

1 · Reply

anachartanalyst Sep. 9 at 7:02 PM

$MYGN https://anachart.com/wp-content/uploads/2026/09/1788980506_soc-img.jpg

0 · Reply

t2026 Sep. 4 at 7:48 PM

$MYGN https://myriad.com/oncology/precise-mrd-test/ Tempus just underpaid and stole $PSNL for a billion and a half dollars Tempus paid 600 million for AMBRY Their MRD platform is legit. Can’t wait to see this marketcap soar 2027 - 2028 story buy it in 2026 !!!!

0 · Reply

SQUEAKSBANDIT Sep. 1 at 4:45 PM

$MYGN Piper Sandler double downgraded Myriad Genetics to Underweight from Overweight with a price target of $2, down from $5.45. Piper does not believe Myriad's current business model can grow or cut its way to profitability. Divestiture of assets is the most credible path to value, the analyst tells investors in a research note. The company ran a strategic review in Q1 of 2025 and elected to not divest or sell assets, which indicates limited strategic interest, adds Piper.

1 · Reply

notreload_ai Sep. 1 at 10:35 AM

Piper Sandler double-downgraded $MYGN, saying the current model cannot grow or cut its way to profit. https://notreload.xyz/xy/mygn-cut-to-underweight-as-piper-questions-path-to-profit/

0 · Reply

t2026 Aug. 27 at 11:54 AM

$MYGN if you liked $PSNL Don’t sleep on this Called that one at 5, called RVMD And now I’m calling this sleeper in the MRD field. $PSNL didn’t have the salesforce. Myriad is in 50 plus percent of cancer offices This is a multi bagger. I’m all in, get in while you can 2027 this rockets, hopefully not sooner I need to build this position

1 · Reply

Zrahimi Aug. 18 at 6:51 PM

$MYGN back 2.85 this will rebound a bit

0 · Reply

revoltingtrees Aug. 18 at 5:14 PM

$MYGN i smell a buyout. 10k shares avg cost $2.88

1 · Reply

revoltingtrees Aug. 18 at 3:47 PM

$MYGN $NVDA

0 · Reply

revoltingtrees Aug. 14 at 6:01 PM

$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!

1 · Reply

Myriad Genetics Transcript: Wells Fargo 21st Annual Healthcare Conference

2026-09-09T11:30:24.000Z - 4 days ago

Myriad Genetics assumed with a Neutral at UBS

Sep 1, 2026, 12:37 PM EDT - 12 days ago

This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.

2026-09-01T09:20:24.000Z - 12 days ago

Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler

Aug 27, 2026, 9:05 AM EDT - 17 days ago

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

2026-08-18T10:35:22.000Z - 26 days ago

Myriad Genetics price target lowered to $3 from $5 at Stephens

Aug 8, 2026, 2:57 PM EDT - 5 weeks ago

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Aug 4, 2026, 11:27 AM EDT - 5 weeks ago

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

2026-08-03T11:41:18.000Z - 5 weeks ago

Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

2026-08-03T11:32:10.000Z - 5 weeks ago

Myriad Genetics price target lowered to $3.20 from $4 at BofA

2026-07-31T12:59:45.000Z - 6 weeks ago

Myriad Genetics price target lowered to $4 from $6 at TD Cowen

2026-07-30T20:45:44.000Z - 6 weeks ago

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

2026-07-30T20:40:31.000Z - 6 weeks ago

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

Jul 30, 2026, 4:30 PM EDT - 6 weeks ago

Myriad Genetics Earnings Call Transcript: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 6 weeks ago

Myriad Genetics Earnings release: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 6 weeks ago

Myriad Genetics Slides: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 6 weeks ago

Myriad Genetics Quarterly report: Q2 2026

Jul 30, 2026, 4:05 PM EDT - 6 weeks ago

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Jul 23, 2026, 9:05 AM EDT - 7 weeks ago

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Jul 21, 2026, 9:05 AM EDT - 7 weeks ago

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Jul 2, 2026, 9:05 AM EDT - 2 months ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Jun 23, 2026, 9:05 AM EDT - 2 months ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Jun 4, 2026, 10:00 AM EDT - 3 months ago

Myriad Genetics Transcript: AGM 2026

2026-06-02T14:16:51.000Z - 3 months ago

Myriad Genetics appoints Raj Jampa as chief technology officer

Jun 2, 2026, 9:05 AM EDT - 3 months ago

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

May 27, 2026, 9:05 AM EDT - 3 months ago

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

2026-05-26T20:39:25.000Z - 3 months ago

Myriad Genetics launches Prolaris + AI

May 26, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 15, 2026, 11:00 AM EDT - 4 months ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 7, 2026, 4:05 PM EDT - 4 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

2026-05-07T05:11:29.000Z - 4 months ago

Myriad Genetics price target lowered to $6 from $7 at TD Cowen

May 5, 2026, 4:30 PM EDT - 4 months ago

Myriad Genetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Myriad Genetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Myriad Genetics Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Myriad Genetics Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 4 months ago

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Apr 30, 2026, 9:05 AM EDT - 4 months ago

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Apr 28, 2026, 4:05 PM EDT - 4 months ago

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

2026-04-16T13:42:01.000Z - 5 months ago

Myriad Genetics to deliver six abstracts at AACR 2026

Apr 16, 2026, 9:15 AM EDT - 5 months ago

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Apr 14, 2026, 9:15 AM EDT - 5 months ago

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Myriad Genetics Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Myriad Genetics Proxy statement: Proxy filing

Apr 9, 2026, 9:15 AM EDT - 5 months ago

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

2026-03-17T20:20:19.000Z - 5 months ago

Myriad Genetics announces FDA approval for MyChoice CDx Test

Mar 17, 2026, 4:05 PM EDT - 5 months ago

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Mar 10, 2026, 1:40 PM EDT - 6 months ago

Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 3:10 PM EST - 6 months ago

Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-24T21:25:02.000Z - 6 months ago

Myriad Genetics files $200M mixed securities shelf

2026-02-24T14:07:41.000Z - 6 months ago

Myriad Genetics to present six abstracts at ASCO-GU 2026

2026-02-24T13:02:15.000Z - 6 months ago

Myriad Genetics price target lowered to $6 from $8 at UBS

Feb 24, 2026, 7:00 AM EST - 6 months ago

Myriad Genetics Registration statement: Registration Filing

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Slides: Q4 2025

Feb 23, 2026, 4:05 PM EST - 6 months ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 19, 2026, 9:15 AM EST - 6 months ago

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 16, 2026, 4:15 PM EST - 6 months ago

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Jan 14, 2026, 8:15 PM EST - 8 months ago

Myriad Genetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 8 months ago

Myriad Genetics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 8 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 5, 2026, 4:15 PM EST - 8 months ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:00 PM EST - 9 months ago

Myriad Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:15 PM EST - 9 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 18, 2025, 1:20 PM EST - 9 months ago

Myriad Genetics Transcript: Wolfe Research Healthcare Conference 2025

Nov 11, 2025, 9:00 AM EST - 10 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Slides: Q3 2025

Nov 3, 2025, 4:05 PM EST - 10 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Oct 31, 2025, 9:05 AM EDT - 10 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 27, 2025, 4:15 PM EDT - 10 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 8, 2025, 5:21 PM EDT - 11 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Sep 23, 2025, 8:01 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 10, 2025, 7:45 AM EDT - 1 year ago

Myriad Genetics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 7:00 PM EDT - 1 year ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 3:45 PM EDT - 1 year ago

Myriad Genetics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:30 PM EDT - 1 year ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 13, 2025, 8:00 AM EDT - 1 year ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Slides: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Myriad Genetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 10:00 AM EDT - 1 year ago

Myriad Genetics Transcript: AGM 2025

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

May 27, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

OkieDokieTrader Sep. 11 at 4:03 PM

$MYGN literally at the edge of a massive break out. The wick from todays opening is all I needed to enter.

1 · Reply

anachartanalyst Sep. 9 at 7:02 PM

$MYGN https://anachart.com/wp-content/uploads/2026/09/1788980506_soc-img.jpg

0 · Reply

t2026 Sep. 4 at 7:48 PM

0 · Reply

SQUEAKSBANDIT Sep. 1 at 4:45 PM

1 · Reply

notreload_ai Sep. 1 at 10:35 AM

Piper Sandler double-downgraded $MYGN, saying the current model cannot grow or cut its way to profit. https://notreload.xyz/xy/mygn-cut-to-underweight-as-piper-questions-path-to-profit/

0 · Reply

t2026 Aug. 27 at 11:54 AM

1 · Reply

Zrahimi Aug. 18 at 6:51 PM

$MYGN back 2.85 this will rebound a bit

0 · Reply

revoltingtrees Aug. 18 at 5:14 PM

$MYGN i smell a buyout. 10k shares avg cost $2.88

1 · Reply

revoltingtrees Aug. 18 at 3:47 PM

$MYGN $NVDA

0 · Reply

revoltingtrees Aug. 14 at 6:01 PM

$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!

1 · Reply

FeliciaMath Aug. 13 at 5:05 PM

$MYGN sold at 3.17. made $52 /3%

0 · Reply

Estimize Aug. 10 at 1:15 PM

Wall St is expecting -0.07 EPS for $MYGN Q1 [Reporting 10/27 AMC] http://www.estimize.com/intro/mygn?chart=historical&metric_name=eps&utm_c

0 · Reply

GoCoogs Aug. 4 at 6:47 PM

$MYGN Rebound rally in motion. Got in at 2.95.

0 · Reply

FeliciaMath Aug. 4 at 4:48 PM

bought $MYGN at 3.09

0 · Reply

theBigDollarski Aug. 3 at 7:38 PM

$MYGN this company needs to get bought out to a firm that can properly market a product and run a company. This management is horrible.

0 · Reply

AnalyticaInvestor Aug. 3 at 10:15 AM

Good morning, investors. Hyperscalers continue accelerating AI infrastructure spending, supporting demand for semiconductor suppliers, networking companies, and specialized hardware providers. Among gainers, $CIGL surged 33% on unusually heavy trading despite no company specific catalyst. On the downside, $MYGN fell 47% after disappointing quarterly results, while $CERS dropped 26% following post earnings selling pressure. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/yields-spike-myriad-down-47

0 · Reply

ShKumaresan Aug. 3 at 3:12 AM

$RBLX $HTZ $MYGN Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? https://stocktwits.com/news-articles/default/equity/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n

0 · Reply

StocktwitsNews Aug. 3 at 3:12 AM

Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? $RBLX $HTZ $MYGN https://stocktwits.com/news/equity/markets/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n

0 · Reply

JustBen47 Aug. 1 at 6:34 PM

$MYGN Not looking good at all

0 · Reply

Ric_1M Aug. 1 at 2:18 PM

$KPTI $BIOA $NUWE $DFNS $MYGN “Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.” Thomas Edison

0 · Reply

james899 Jul. 31 at 8:50 PM

$MYGN woah what's going on, bankruptcy incoming?

0 · Reply

Gmblr777 Jul. 31 at 8:45 PM

$MYGN buying

0 · Reply

Market Cap	327.12M
Revenue (ttm)	824.50M
Net Income (ttm)	-365.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-44.38%
Debt to Equity Ratio	0.40

Volume	2,552,900
Avg Vol	1,886,346
Day's Range	N/A - N/A
Shares Out	95.65M
Stochastic %K	99%
Beta	1.68
Analysts	Hold
Price Target	$3.33